Document is current

Article History

Received: 21 October 2020

Accepted: 21 January 2021

First Online: 4 February 2021

Ethics approval and consent for participation

: All participants signed the informed consent approved by the ethics committees of the participating centers (Hospital Universitario la Candelaria, Tenerife; Spain; IRB No. 258/2009). This manuscript does not contain any individual person’s data.

: Not applicable.

: MCR has received speaking fees from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Menarini and Novartis, and consulting fees from GlaxoSmith¬Kline, Gebro Pharma and Novartis. There is no real or perceived conflict of interest between these sources and the present paper. JLRH has received speaking fees from Boehringer Ingelheim and Gebro Pharma. There is no real or perceived conflict of interest between these sources and the present paper. JPT does not have a real or perceived conflict of interest. JMM does not have a real or perceived conflict of interest. CMG does not have a real or perceived conflict of interest. AF does not have a real or perceived conflict of interest. BC reports grants, personal fees and non-financial support from GSK; grants, personal fees and non-financial support from Chiesi; grants, personal fees and non-financial support from Astrazeneca; grants from Menarini and Boehringer-Ingheilm; non-financial support from Novartis; personal fees and non-financial support from Sanofi, outside the submitted work. GPB reports grants, personal fees and non-financial support from GSK, Boehringer Ingelheim, Chiesi and Orion Pharma. There is no real or perceived conflict of interest between these sources and the present paper. IS does not have a real or perceived conflict of interest. NFC does not have a real or perceived conflict of interest. JLLC reports personal fees and non-financial support from AstraZeneca; grants, personal fees and non-financial support from Boehringer Ingelheim; grants, personal fees and non-financial support from Chiesi; personal fees and non-financial support from CSL Behring; grants, personal fees and non-financial support from Esteve; personal fees and non-financial support from Ferrer; grants, personal fees and non-financial support from GebroPharma; grants, personal fees and non-financial support from GlaxoSmithKline; grants, personal fees and non-financial support from Grifols; grants, personal fees and non-financial support from Menarini; grants, personal fees and non-financial support from Novartis; grants, personal fees and non-financial support from Rovi; and grants, personal fees and non-financial support from Teva, outside the submitted work. CC has received speaker fees from Novartis, Menarini, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline and Teva, and consulting fees from AstraZeneca, Esteve, GlaxoSmithKline and Novartis.